ArticleFrontiers in immunology2025

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system.

Chen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.